Nanomedicine News RSS Feed - Nanomedicine

NanoSIMS Helps Trace How Liver, Brain Cells Store and Metabolize Glycogen

NanoSIMS Helps Trace How Liver, Brain Cells Store and Metabolize Glycogen

Scientists at EPFL have used a new imaging technique to monitor how glucose, our main energy source, is used in the body. Their findings may have great implications for diseases like diabetes. [More]
Nanoscale Device Can Rapidly Gauge Optimal Dose of Potentially Toxic Cancer Drug

Nanoscale Device Can Rapidly Gauge Optimal Dose of Potentially Toxic Cancer Drug

In less than a minute, a miniature device developed at the University of Montreal can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug. Just as accurate and ten times less expensive than equipment currently used in hospitals, this nanoscale device has an optical system that can rapidly gauge the optimal dose of methotrexate a patient needs, while minimizing the drug's adverse effects. The research was led by Jean-François Masson and Joelle Pelletier of the university's Department of Chemistry. [More]
CASIS Awards Grant to Develop Remotely Controlled Nanochannel Drug Delivery System

CASIS Awards Grant to Develop Remotely Controlled Nanochannel Drug Delivery System

Houston Methodist Research Institute scientists will receive about $1.25 million from the Center for the Advancement of Science in Space to develop an implantable device that delivers therapeutic drugs at a rate guided by remote control. The device's effectiveness will be tested aboard the International Space Station and on Earth's surface. [More]
Novel Nanoparticle Delivers Melanoma-Fighting Drug Directly to the Cancer

Novel Nanoparticle Delivers Melanoma-Fighting Drug Directly to the Cancer

Penn State College of Medicine researchers have developed a nanoparticle to deliver a melanoma-fighting drug directly to the cancer. [More]
New Report on Global Market for Anti-Microbial Nanocoatings

New Report on Global Market for Anti-Microbial Nanocoatings

Research and Markets has announced the addition of the "The Global Market for Anti-Microbial Nanocoatings" report to their offering. [More]
Smarter, More Targeted Nanotherapy Could Overcome Lethal Gynecologic Cancer

Smarter, More Targeted Nanotherapy Could Overcome Lethal Gynecologic Cancer

Physicians will tell you: They are not winning the war on ovarian cancer. But Florida International University researchers are crafting a new weapon for that battle. A group of scientists have combined medicine and advanced nanotechnological engineering to create a smarter, more targeted therapy that could overcome the most lethal gynecologic cancer. [More]
Tiny ‘Nanodomain’ Structures with Concentrated ANK3 Gene Levels Linked to Bipolar Disorder

Tiny ‘Nanodomain’ Structures with Concentrated ANK3 Gene Levels Linked to Bipolar Disorder

A nano-sized discovery by Northwestern Medicine® scientists helps explain how bipolar disorder affects the brain and could one day lead to new drug therapies to treat the mental illness. [More]
Hybrid Diagnostic ‘Nanodecoder’ for Improvement of Cancer Treatment

Hybrid Diagnostic ‘Nanodecoder’ for Improvement of Cancer Treatment

Cancer diagnostics and treatment options could be drastically improved with the creation of a ‘designer’ nanodevice being developed by researchers from the UK, Italy, the US and Argentina. [More]
NuVascular Commercializes Nanotechnology-Based Electrospinning Process for Creating Medical Devices

NuVascular Commercializes Nanotechnology-Based Electrospinning Process for Creating Medical Devices

NuVascular Technologies, Inc. is commercializing its patented electrospinning process to create new medical devices that help millions. [More]
French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma

French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma

NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). [More]